1. N,N-Dimethylformamide Delays LPS-Induced Preterm Birth in a Murine Model by Suppressing the Inflammatory Response.
- Author
-
Wei ZH, Salami OO, Koya J, Munnangi S, Pekson R, Ashby CR Jr, and Reznik SE
- Subjects
- Acetamides, Animals, Anti-Inflammatory Agents pharmacology, Disease Models, Animal, Excipients adverse effects, Female, Humans, Infant, Newborn, Inflammation chemically induced, Inflammation drug therapy, Inflammation prevention & control, Interleukin-6, Interleukin-8, Lipopolysaccharides pharmacology, Mice, NF-KappaB Inhibitor alpha, NF-kappa B metabolism, Placenta metabolism, Pregnancy, Solvents adverse effects, Tumor Necrosis Factor-alpha, Dimethylformamide adverse effects, Premature Birth chemically induced, Premature Birth prevention & control
- Abstract
Preterm birth accounts for the majority of perinatal mortality worldwide, and there remains no FDA-approved drug to prevent it. Recently, we discovered that the common drug excipient, N,N-dimethylacetamide (DMA), delays inflammation-induced preterm birth in mice by inhibiting NF-κB. Since we reported this finding, it has come to light that a group of widely used, structurally related aprotic solvents, including DMA, N-methyl-2-pyrrolidone (NMP) and dimethylformamide (DMF), have anti-inflammatory efficacy. We show here that DMF suppresses LPS-induced TNFα secretion from RAW 264.7 cells and IL-6 and IL-8 secretion from HTR-8 cells at concentrations that do not significantly affect cell viability. Like DMA, DMF protects IκBα from degradation and prevents the p65 subunit of NF-κB from translocating to the nucleus. In vivo, DMF decreases LPS-induced inflammatory cell infiltration and expression of TNFα and IL-6 in the placental labyrinth, all to near baseline levels. Finally, DMF decreases the rate of preterm birth in LPS-induced pregnant mice (P<.0001) and the rate at which pups are spontaneously aborted (P<.0001). In summary, DMF, a widely used solvent structurally related to DMA and NMP, delays LPS-induced preterm birth in a murine model without overt toxic effects. Re-purposing the DMA/DMF/NMP family of small molecules as anti-inflammatory drugs is a promising new approach to delaying or reducing the incidence of inflammation-induced preterm birth and potentially attenuating other inflammatory disorders as well., (© 2022. Society for Reproductive Investigation.)
- Published
- 2022
- Full Text
- View/download PDF